ReviewHuman vaccines & immunotherapeutics2026
The current role of immunotherapy in treating nasopharyngeal carcinoma.
Review in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunotherapy has emerged as a cornerstone in the management of both recurrent/metastatic nasopharyngeal carcinoma (R/M NPC) and locoregionally advanced NPC (LANPC). Evidence indicates that programmed death-1/programmed death ligand-1 (PD-1/PD-L1) inhibitors, whether administered as monotherapy or in combination with chemotherapy or antiangiogenic agents, can significantly improve outcomes in R/M NPC. For LANPC, incorporating immunotherapy into induction, concurrent chemoradiotherapy, and adjuvant phases has demonstrated potential benefits in enhancing antitumor immune responses and reducing the incidence of disease recurrence. However, challenges persist regarding the identification of optimal patient populations, the determination of optimal timing and duration of treatment, and the management of immune-related adverse events. Biomarkers such as PD-L1 expression and plasma Epstein-Barr virus-DNA levels show promise in facilitating risk stratification and tailoring individualized treatment regimens. Accordingly, this review provides a comprehensive review of immunotherapy for NPC, evaluating current progress an persistent challenges by drawing insights from both completed and ongoing clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.